Alpha-fetoprotein and Its Receptor in Fixing the Cancer Brakes

This book examines the crucial role of a unique alpha-fetoprotein (AFP) in the treatment of cancer. AFP can deliver toxins through specific receptors re-expressed in the majority of cancer cells, serving as a targeted chemotherapy. More importantly, AFP+toxin harnesses the patient’s immune system in order to attack cancer. Depleting the regulatory top monocyte-derived suppressor cells (MDSCs) activates both the innate and adaptive immune responses. The thoroughly chosen toxins switch on apoptosis in MDSCs, restore the broken one in cancer cells, and destroy them naturally without any harmful by-products. Injections with AFP+toxin preparations have shown promising results in animals and the treatment of cancer patients. In addition to this breakthrough, the book also discusses the peroral administration of porcine AFP non-covalent complexes with selected toxins in patients with metastases. It will appeal to science researchers, clinicians, and medical students, as well as the more general reader. About the Author Dr Vladimir N. Pak received his PhD from the Institute of Bioorganic Chemistry, Moscow, before working at the Novosibirsk Institute of Molecular Biology, Russia, and other biotechnological companies. He has over 35 years of experience in genetic engineering, virology, immunology, and biotechnology. His work focuses on the manufacturing of drugs (Lidasum, Ingitril) and the implementation of the drug-candidates based on injectable (Reducin) and peroral (Aimpila) forms of AFP+toxin(s) non-covalent complexes. He is the author of numerous scientific articles and one book chapter.